When vaccines reset tumors: SARS-CoV-2 mRNA shots create a transient checkpoint-sensitive state

In a recent study published in Nature, Grippin and colleagues showed that SARS-CoV-2 mRNA vaccines can transiently reset the tumor–immune interface, converting immunologically “cold” tumors into those that respond to PD-1/PD-L1 blockade. This work supports COVID-19 mRNA vaccines as systemic immune modulators that, when timed appropriately around immune checkpoint inhibitors (ICIs), can sensitize tumors and improve survival across diverse cancer types. 1